Musculoskeletal Disorders
Conference Coverage
Comorbidities emerge in adulthood for many patients with JIA
More than half of these patients have at least one comorbidity.
Conference Coverage
Antacid use in infants linked to increased fracture risk
Proton pump inhibitors apparently are not as benign as once thought.
Pearce-Ings
Pes planus: To treat or not to treat
Classifying the type of flat feet a child has is the first of several difficulties in treating this common problem.
From the Journals
Methotrexate prolonged efficacy of steroid injections in oligoarticular JIA
The combination of intra-articular corticosteroids and methotrexate could take center stage in treat-to-target strategies for children with...
From the Journals
Opinions vary considerably on withdrawing drugs in clinically inactive JIA
There’s no one way to stop or taper medications for young patients with clinically inactive JIA.
From the Journals
Genetic studies link JIA subtypes to adult diseases, show uniqueness of systemic disease
Two new studies of the genetic relationships between the seven designated categories of juvenile idiopathic arthritis provide compelling support...
News from the FDA/CDC
First drug for spinal muscular atrophy approved
The antisense oligonucleotide drug nusinersen is the first therapy approved by the U.S. Food and Drug Administration to treat children and adults...
Conference Coverage
VIDEO: TNF inhibitors don’t boost cancer risk in JIA
WASHINGTON – Tumor necrosis factor inhibitors don't appear to confer any additional cancer risk upon children with juvenile idiopathic arthritis...
From the Journals
Most children with JIA get different diagnosis as adults
Two-thirds of children diagnosed with juvenile idiopathic arthritis are classified later as having a different form of arthritis as adults, with...
News
SHARE initiative releases consensus-based JDM management recommendations
Early and aggressive therapy may prevent or stabilize organ damage and disease-related complications in patients with juvenile dermatomyositis (...
Conference Coverage
VIDEO: TNF inhibitors improved refractory skin disease in juvenile dermatomyositis
Key clinical point: TNF inhibitor treatment in patients with juvenile dermatomyositis may be beneficial for skin involvement that is refractory to...